SightfileU.S. market data from official filings

DESIGN THERAPEUTICS INC (DSGN)

Name: DESIGN THERAPEUTICS INC (DSGN) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001807120 · EDGAR filings · Updated 2026-06-11

DESIGN THERAPEUTICS INC (DSGN) has reported institutional ownership of 60.8%, with 125 institutional managers holding positions valued at $404.1M per the latest 13F reporting period.

Institutional ownership

60.8%

Institutional managers

125

Reported 13F value

$404.1M

Insider activity

2 trans.

−$2.95M net selling

Latest updates

2026-06-11 — Insider transaction reported (Form 4)
2026-06-11 — Insider transaction reported (Form 4)
2026-06-11 — Insider transaction reported (Form 4)
2026-06-11 — Insider transaction reported (Form 4)
2026-06-11 — Insider transaction reported (Form 4)
2026-06-11 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, DESIGN THERAPEUTICS INC has 125 institutional holders and institutional ownership of 60.8%.

Insider activity

Insiders reported 2 transactions (0 buys, 2 sells) across 1 reporting insiders, with a net reported value of −$2.95M.

Related companies

TECTONIC THERAPEUTIC INC (TECX) · ACLARIS THERAPEUTICS (ACRS) · UPSTREAM BIO INC (UPB) · LARIMAR THERAPEUTICS INC (LRMR) · ZURA BIO LTD (ZURA) · ZEVRA THERAPEUTICS INC (ZVRA)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-06-11.